(2R)-2-Ethyl-2,3-dihydro-6-(trifluoromethyl)quinolin-4(1H)-one (CAS: 952582-00-2) is a chiral, fluorine-containing fused heterocyclic compound belonging to the dihydroquinolin-4(1H)-one family, with the molecular formula C₁₂H₁₂F₃NO and a molecular weight of 243.23 g/mol. Its core structure — a 2,3-dihydroquinolin-4(1H)-one scaffold featuring an ethyl substituent at the chiral 2‑position and a trifluoromethyl group at the 6‑position — provides a conformationally rigid pharmacophore platform highly suitable for targeted drug design. The presence of the chiral (2R)-center and the powerful electron‑withdrawing trifluoromethyl substituent (‑CF₃) combine to impart enhanced metabolic stability, improved binding affinity to biological targets, and favorable physicochemical properties for oral bioavailability.
This compound has been identified as a potent CRTH2 (chemoattractant receptor‑homologous molecule expressed on Th2 cells) antagonist. CRTH2 is a high‑affinity receptor for prostaglandin D₂ (PGD₂), a key mediator involved in type 2 inflammatory responses. Activation of CRTH2 by PGD₂ plays a critical role in the recruitment of Th2 cells, eosinophils, and basophils to inflamed tissues in allergic asthma, atopic dermatitis, allergic rhinitis, and other eosinophilic inflammatory disorders. Antagonists of the CRTH2 receptor, therefore, represent an important and actively pursued therapeutic strategy for the treatment of these allergic and inflammatory diseases. The binding affinity data confirm that quinolinone derivatives of this class engage the CRTH2 target: assays report IC₅₀ values of 85 nM (PGD₂-induced [³⁵S]GTPγS binding in CHO cells) and 50 nM (PGD₂-induced calcium flux in HEK293 cells), establishing the scaffold as a potent inhibitor of CRTH2-mediated signaling pathways.
In addition to its role as a CRTH2 antagonist, dihydroquinolin-4(1H)-one scaffolds have been reported as promising tubulin polymerization inhibitors targeting the colchicine binding site. A series of novel dihydroquinolin-4(1H)-one derivatives have been designed, synthesized, and evaluated as anticancer agents acting via microtubule disruption. The unique bicyclic structure allows for optimization of anti-proliferative activity while maintaining selectivity, highlighting the scaffold‘s potential beyond anti-inflammatory applications. Furthermore, quinolinone-based FGFR inhibitors have also been disclosed, and the trifluoromethylquinoline motif is increasingly recognized as a privileged structure in the design of dual-target therapeutic agents spanning oncology, inflammation, and central nervous system disorders. The compound is therefore positioned at the intersection of several high-value drug discovery programs: anti‑inflammatory, anti‑allergic, anti‑cancer, and antiviral. From the perspective of synthetic accessibility, fluorinated 2,3-dihydroquinolin-4(1H)-one derivatives can be constructed in good to high yields (up to 98 %) and excellent diastereoselectivities (dr up to 99/1) under mild reaction conditions using simple starting materials, ensuring scalable and cost‑effective synthesis.
The global market for dihydroquinolin-4(1H)-one derivatives was valued at approximately USD 1.8 billion in 2024 and is projected to expand to USD 3.0 billion by 2032, representing a compound annual growth rate (CAGR) of 6.8 %. The CRTH2 antagonist sub‑segment is expected to grow at an even faster CAGR of 8‑10 %, driven by the rising global prevalence of allergic asthma and atopic dermatitis, increasing patient demand for safer, non‑steroidal therapeutic options, and the expanding pipeline of CRTH2‑targeted drug candidates entering clinical trials. The overall global antidepressant market (which partly relies on related heterocyclic API intermediates) was valued at USD 15.3 billion in 2024 and is projected to reach USD 17.6 billion by 2030, growing at a CAGR of 2.5 %. The broader respiratory and inflammatory disease API intermediate market — including CRTH2 antagonists — is expanding at 6‑8 % annually.
Major pharmaceutical companies and emerging biotechs are actively screening CRTH2 antagonist libraries for the treatment of severe asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, food allergy, and eosinophilic esophagitis. This has driven corresponding demand for building blocks such as (2R)-2-ethyl-2,3-dihydro-6-(trifluoromethyl)quinolin-4(1H)-one in early‑stage medicinal chemistry and process development. The dihydroquinolin-4(1H)-one derivatives market size was estimated at approximately USD 2.3 billion in 2025, with a projected increase to USD 3.6 billion by 2033. Leading players in the CRTH2 antagonist development pipeline include large pharmaceutical companies and specialized biotech firms, complemented by a network of CRO/CDMOs that outsource custom synthesis of heterocyclic intermediates. Asia‑Pacific, and China in particular, has emerged as the dominant manufacturing hub for pharmaceutical intermediates, supplying custom‑synthesized building blocks at competitive costs to both domestic and international R&D operations. North America and Europe command the largest share of pharmaceutical R&D consumption, with the highest concentration of CRTH2‑targeting drug discovery programs and stringent quality requirements (≥99 % purity, full enantiomeric purity documentation, ICH Q3D compliance for heavy metals, and full product traceability).
The compound should be stored at 2‑8 °C in a tightly sealed container, protected from light, moisture, strong oxidizing agents, and strong acids. In the European Union, it is subject to REACH regulations; importers and manufacturers must provide Safety Data Sheets (SDS). In the United States, it is regulated under TSCA as a research chemical; for pharmaceutical API use, adherence to cGMP guidelines (21 CFR Parts 210/211) is required. In China, it is listed in the Inventory of Existing Chemical Substances (IECSC) and requires safety production licenses for manufacturing facilities.
Looking forward, the market outlook for this compound is tied to four core drivers: (1) the continued expansion of the global respiratory and allergic disease drug market, with CRTH2 antagonists advancing through the clinical pipeline; (2) the increasing adoption of chiral, fluorinated intermediates that offer enhanced metabolic stability in drug candidates; (3) the rapid growth of Asian CRO/CDMO sectors supplying intermediates to global pharmaceutical companies; and (4) the privileged position of the dihydroquinolinone scaffold in fragment‑based drug discovery (FBDD) programs. Enterprises should focus on securing high‑purity chiral production capabilities, maintaining rigorous impurity documentation for pharmaceutical regulatory filings, and building long‑term supply partnerships with API manufacturers, CROs, and research institutions.
Shanghai XinChem Co., Ltd.
As a world‑leading supplier of pharmaceutical intermediates and heterocyclic building blocks, Shanghai XinChem Co., Ltd. (XinChem) has always focused on the innovative needs of the targeted therapeutics, anti‑inflammatory drug discovery, and respiratory API industries. Relying on core advantages in chiral heterocyclic synthesis, purification, and quality assurance, we provide high‑quality (2R)-2-ethyl-2,3-dihydro-6-(trifluoromethyl)quinolin-4(1H)-one (CAS 952582-00-2) to global customers.
1. Technical Advantages
- High Purity & Chiral Consistency: Our product achieves purity ≥97‑98 % (by HPLC), white to off‑white crystalline solid, molecular weight 243.23 g/mol, molecular formula C₁₂H₁₂F₃NO, and moisture <0.5 % (KF titration). The (2R)‑chirality is preserved throughout synthesis and verified by chiral HPLC, ensuring stereospecific performance in target engagement assays.
- Low Impurity Profile: Strict control of residual solvents ( <0.5 % total ), heavy metals ( ≤10 ppm, ICH Q3D compliant ), and related substances by HPLC‑UV, ensuring high synthetic performance for medicinal chemistry scale‑up.
- Batch‑to‑Batch Uniformity: Rigorous analytical testing (HPLC, NMR, LC‑MS, heavy metals by ICP‑MS, residual solvents by GC‑headspace) guarantees consistent quality across all production lots.
2. Product Advantages
- Potent CRTH2 Antagonist Scaffold: The trifluoromethyl‑substituted dihydroquinolinone core directly serves as a CRTH2 antagonist pharmacophore, with reported IC₅₀ values in the nanomolar range against the human receptor.
- Privileged Heterocyclic Framework: Widely employed in medicinal chemistry campaigns targeting respiratory and allergic diseases, oncology, and CNS disorders, offering rapid SAR exploration via derivatization at multiple positions.
- Scalable & Reproducible Synthesis: Multi‑step heterocyclic synthesis has been demonstrated at multi‑kilogram scale with excellent diastereoselectivity (up to 99/1), enabling seamless transition from research grams to bulk pharmaceutical production.
- Flexible Packaging Options: 5 g, 10 g, 25 g, 50 g, 100 g, 500 g, 1 kg glass bottles/HDPE containers (R&D/pilot); 5 kg, 10 kg, 25 kg fiber drums (industrial). Full custom packaging available for pharmaceutical campaigns.
- Reliable Supply Chain: Annual capacity 50‑200 kg, with dedicated temperature‑controlled warehousing (2‑8 °C, light‑protected, sealed containers) and just‑in‑time delivery capabilities.
3. Application Fields
- Pharmaceutical Intermediates: Key building block for CRTH2 antagonists for allergic asthma, atopic dermatitis, and allergic rhinitis; chemokine receptor modulators; tubulin polymerization inhibitors for anticancer therapy; FGFR inhibitors; and heterocyclic drug candidates for respiratory and inflammatory diseases.
- Respiratory & Allergic Disease APIs: Core scaffold for next‑generation non‑steroidal anti‑inflammatory drugs (NSAIDs) targeting the PGD₂/CRTH2 pathway.
- CRO/CDMO Custom Synthesis: Essential custom‑synthesized intermediate for medicinal chemistry outsourcing, hit‑to‑lead optimization, and preclinical toxicology studies.
- Oncology Drug Discovery: Scaffold for tubulin polymerization inhibitors (colchicine binding site), FGFR inhibitors, and dual‑target anti‑cancer agents.
- Drug Discovery Library Construction: Enabling building block for fragment‑based drug discovery (FBDD), structure‑activity relationship (SAR) campaigns, and high‑throughput screening library production.
4. Service Support
Our technical team provides full impurity profiling (chiral purity by chiral HPLC, residual solvents by GC‑headspace, heavy metals by ICP‑MS, LC‑MS identity confirmation), custom purification to any desired specification, and complete regulatory documentation (Certificate of Analysis, Technical Data Sheet, Safety Data Sheet, REACH compliance, TSCA certification, DMF support for pharmaceutical customers). We also offer custom synthesis of trifluoromethyl quinolinone derivatives, cold‑chain logistics, and just‑in‑time delivery.
5. Why Choose XinChem
- Professionalism: 20+ years in the pharmaceutical intermediate and heterocyclic synthesis industry.
- Flexibility: Tailored to customer purity specifications, chiral purity documentation, packaging sizes, and regulatory documentation requirements.
- Cost‑effectiveness: High purity at competitive industrial pricing.
Contact us now to start cooperation!
Website: www.xinchem.com
Email: sales1@xinchem.com
WhatsApp: +86 18049800532
Post time: Jun-01-2026